· Health Care Equipment · S&P SmallCap 600
IART INTEGRA LIFESCIENCES HOLDINGS $1.2B
No. AI shows up as regulation and as a cyber threat.
1 of 15
Reach, Weight, and Proof.
Last updated score 31 AugLast review 29 OctLast earnings call 21 OctNext earnings call not posted yet
What they are doing
Integra's 10-K does not describe an AI product in surgery or tissue. It says the EU AI Act and new state AI laws will raise compliance cost, and that attackers may use AI tools. A line that adoption of AI tools by the company or by others may create new cyber challenges is a risk, not a named program. The 21 October 2026 call, including the questions, named no artificial-intelligence product. The score stays 1.
Why the score
- Reach 0 not 1: no operating function.
- Weight 0 not 1: no experiment we can point at.
- Proof 1 not 0: the words are in the risk factors.
- Proof 1 not 2: not tied to a live use.
What would move it next quarter: A named intelligence layer in a surgical or tissue product.
Open these first
Evidence
Broad availability of artificial intelligence technologies is driving more regulation, including the EU AI Act and AI laws in U.S. states, and compliance will likely be a rising cost. Adoption of AI tools by the company or by third parties may pose new cybersecurity challenges. Threat actors may use AI tools to automate attacks.